As expected, the European Commission approves Novartis’ (NYSE:NVS) Mayzent (siponimod) for the treatment of adults with secondary progressive multiple sclerosis with active disease.
Two months ago, the advisory group CHMP adopted a positive opinion backing approval.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.